Other News Items
505 S. Rosa Rd
Madison, WI 53719

2006 November 01
Fourier-Transform SPR Analysis using the SPR100 Demonstrates SPR Response in Conducting Metal Oxides
Surface Plasmon Resonance (SPR) analysis is a well established technique in life science research for monitoring molecular interactions such as antibody-antigen recognition and protein-ligand binding. Advances in GWC’s SPR measurement systems are now leading to the increased use of SPR analysis in materials science applications.

Most SPR systems measure events on gold or silver surfaces, with glass as the supporting dielectric needed to elicit the SPR response. SPR measurement on gold surfaces is an extraordinarily versatile technique in life science, as illustrated by the broad range of life science applications proven for GWC's SPRimager®II analysis platform. As a practical matter, until now, the restriction of measurements to gold or silver surfaces limited the application of SPR analysis in materials science.

Theoretically, the SPR response can be elicited from any conducting material. In a landmark paper published in the Journal of Applied Physics, Rhodes et al. used GWC’s patented technique of Fourier-Transform SPR analysis (FT-SPR) to test whether conditions can be found under which a conducting metal oxide (CMO) elicits the SPR response. Using a modified version of the SPR100 instrument, Rhodes et al. showed for the first time that SPR measurements can be made on the CMO indium tin oxide. Moreover, the work suggests that SPR measurement will be generally applicable to CMOs, establishing the utility of FT-SPR analysis for helping to understand the properties of these complex materials. These results are expected to lead to the use of FT-SPR analysis for materials characterization in the semiconductor industry, where CMOs are routinely used in critical components.

The SPR100 system is marketed by Thermo Electron Corp. under license from GWC Technologies. For more information on the SPR100, please contact your Thermo or GWC Technologies representative or email .

Return to the Top of the Page

2006 October 10
Timothy J. Stultz Appointed to GWC Technologies Board of Directors
GWC Technologies is pleased to announce the appointment of Timothy J. Stultz, PhD to the Board of Directors. Dr Stultz is President & CEO of Imago Scientific Instruments, a rapidly-growing nanotechnology company based in Madison, Wisconsin. According to GWC Technologies’ President & CEO Tim Burland, “Tim Stultz has over 20 years of executive management and strategic development experience in high technology and capital equipment manufacturing, including positions as founder and President of Peak Systems, Inc., President & CEO of ThauMDx, LLC, and VP GM of Veeco Instruments. We are delighted to have such a capable individual on our team to help with our business and funding strategies.” Tim Burland added that among his many accomplishments, Dr Stultz. has extensive experience in raising capital, both private and public, as well as success in several mergers and acquisitions.

GWC Technologies develops, manufactures and markets scientific instruments for researchers in pharmaceutical, biotechnology and academic organizations worldwide. The company’s products serve the rapidly growing “proteomics” market segment, providing detection systems that help researchers to understand protein function.

For more information, please contact Tim Burland, President & CEO, GWC Technologies Inc., 608.441.2722.

Return to the Top of the Page
2006 August 15
Use of SpotReady™ ligand arrays to profile cell surface receptors published in the Journal of Proteome Research
In a collaboration between the laboratory of Lloyd M. Smith at the University of Wisconsin-Madison and GWC Technologies, Peelen et al. fabricated ligand arrays on SpotReady™ chips, using covalent linkage via aldehyde or N-hydroxy succinimidyl (NHS) ester-modified surfaces. When live, whole cell populations of BHK21 cells were exposed to the arrays, the cells attached specifically to the ligands for which they are known to carry cell surface receptors. Exemplar data show specificity of BHK21 attachment to bFGF (basic fibroblast growth factor) ligands but not to cytochrome C control probes. The cells also attached, with intermediate affintiy, to insulin ligands on the array. These results pave the way for efficient cell receptor profiling using ligand arrays on SpotReady™ chips and the SPRimager®II system to monitor binding.

For access to detailed protocols, please contact your GWC Technologies representative or email .

Return to the Top of the Page
2006 July 31
GWC Technologies to support project to characterize monoclonal antibodies that target huntingtin protein
GWC Technologies has agreed to work with the laboratory of Dr. Richard R Burgess in the Department of Oncology at the University of Wisconsin-Madison to characterize monoclonal antibodies that target the huntingtin protein, the abnormal form of which is associated with Huntington’s Disease.

The mAbs to be used in this work were developed by Neoclone Inc., a leading developer and manufacturer of antibodies. These mAbs will be characterized using GWC’s SPRimager®II platform. According to Dr. Burgess, “The beauty of the approach… …is that it is flexible, it does not require that the mAbs be purified prior to use, and it does not require the labeling of any mAb or other protein with radioactivity or fluorescent dyes.” The ability to circumvent antibody purification stems from GWC’s demonstration that functional antibody arrays can be made on SpotReady™ chips by direct spotting of ascites fluid. This approach also serves to preserve valuable reagents since only sub-microliter volumes of ascites fluid are needed in any one experiment.

The project is made possible through an Industrial & Economic Development Research Program grant from the University of Wisconsin-Madison Graduate School to Dr. Burgess. A successful outcome of the project would provide a basis for improved diagnostic and theraputic approaches to Huntington’s disease.

For information on characterizing antibodies using the SPRimager®II platform and SpotReady™ chips, please contact your GWC Technologies representative or email .

Return to the Top of the Page
2006 July 21
GWC Technologies commences drug absorption profiling project with QBI Life Sciences
GWC Technolgies today announced a collaboration with QBI Life Sciences to develop a drug absorption profiling system. QBI has been awarded a Phase I SBIR grant to develop methods to use their PreserveX™ polymeric micelles in drug absorption modelling studies. GWC Technologies is providing array fabrication expertise for the project and analysis services using GWC’s label-free SPRimager®II array platform.

Development of technologies for early drug absorption profiling for novel drug candidates is one of the crucial issues facing modern drug discovery. Current approaches are low-throughput and suffer from difficulties with poor reproducibility and poor compatibility with existing instrumentation. Principal Investigator Dr. Vladimir Trubetskoy, QBI’s Director of Polymer Chemistry, and GWC's Chief Scientific officer, Dr Voula Kodoyianni, plan to overcome these barriers by developing new methods based on the companies’ available products for proteomics research. This novel assay will use a mixture of amphiphilic polymers that can extract membrane proteins and lipids from natural membranes by formation of stable polymeric micelle-membrane component complexes (PM-Mem). The resulting micelles can be effectively immobilized on GWC’s SpotReady™ arrays via polymeric tethers. Each array accommodates multiple spots with biological membrane components extracted from various tissues. This technology provides significant benefits over traditional liposome sensor coatings due to the stability of PM-Mem. The project deliverable is a system for standardized profiling of the absorption characteristics of drug candidates.

Return to the Top of the Page

2006 June 07
GWC's PCR-free, label-free, real-time amplification technology featured in leading review article
In the cover story of issue #12 of Langmuir volume 22, Hye Jin Lee, Alastair W. Wark, and Robert M. Corn highlight the features of GWC’s AmpliFast™ technology for detection of nucleic acid targets. Invented in Dr. Corn’s laboratory, the array-based technology has proven both specific and sensitive for detection of DNA targets. DNA complementary to RNA probes on the array leads to specific degradation of the RNA probes when the enzyme RNase H is added. Loss of RNA probe from the surface is monitored in real time on GWC’s label-free SPRimager®II system. Since the target DNA survives the enzymatic reaction, it is free to hybridize to another RNA probe, leading to further probe loss and higher signals. Amplification of the signal in this way is at least 12,000-fold. This surface enzyme reaction has been thoroughly characterized by Corn and colleagues, and is now established as a robust, quantitative, real-time method for nucleic acid detection. The method also forms the basis of GWC’s proprietary label-free, PCR-free, reverse-transcription-free gene expression analysis technology.

Return to the Top of the Page
2006 June 01
Detailed protocol now available for cell receptor profiling on ligand arrays using the SPRimager®II
GWC Technologies today made available detailed experimental procedures for preparation of protein ligand arrays that can be used to profile the presence of specific receptors on the surfaces of live cells. The exemplar data show that BHK21 cells bind to bFGF (basic fibroblast growth factor) on SpotReady™ protein arrays, but not to cytochrome C controls on the same array. This specificity of cell binding can be used to profile multiple receptors on the same cell population by exposing the cells to SpotReady™ ligand arrays.

For access to detailed protocols, please contact your GWC Technologies representative or email .

Return to the Top of the Page
2006 May 15
SPRimager®II array platform proves its mettle in direct comparison with vastly more expensive system
In a paper published in the premier edition of the journal Calcium Binding Proteins, Subramanian et al. report an improved method for label-free analysis of protein-protein interactions. The work was based on a collaboration between GWC and Arthur Polans' group funded by an Industrial & Economic Development Research Program grant from the University of Wisconsin-Madison Graduate School to Dr. Arthur Polans at the University of Wisconsin, and from GWC Technologies. Subramanian et al. developed a method for fabrication of protein arrays on GWC’s SpotReady™ chips. The method uses engineered proteins tagged with SBP (Streptavidin-Binding Peptide), which has significant advantages over methods that use GST-tagged proteins, a popular alternative. In the landmark paper, the researchers measured the affinity of the interaction between ALG-2 and Annexin XI, an interaction identified as important in the development of certain cancers of the eye. As expected, the measured affinity for the interaction was higher on the open-platform SPRimager®II, which provides for free access of analyte to the protein array. Remarkably, the protein array prepared on GWC’s SpotReady™ chip proved to have dramatically longer functionality, remaining usable for protein interaction analysis after six months of storage.

For advice on protein array fabrication for the SPRimager®II platform, please contact your GWC Technologies representative or email .

Return to the Top of the Page

2006 April 14
GWC Technologies array system featured in Science Magazine product Article
In the Article “Proteomics - Interacting Instruments”, Mike May and Gary Heebner report on products used in protein analysis. The article recounts the versatility of GWC’s SPRimager®II platform and SpotReady™ chips for proteomics research. Read the Science Article.

Return to the Top of the Page
2006 April 12
GWC Technologies presents poster detailing proof of principle for application of AmpliFast™ detection to gene expression analysis
Dr. Christine Angevine, GWC’s Applications Scientist, presented a poster today in the innovation corridor at the BIO2006 conference in Chicago. The poster detailed how the AmpliFast™ method can be used to monitor mRNA levels in whole cell mRNA populations without the use of reverse transcription, target amplification, or fluorescent labelling. Data in the poster demonstrated femtomolar sensitivity of the method for target DNA detection and specificity of the method for target mRNAs. The AmpliFast™ method is based on the published research of GWC co-founder Robert M. Corn and colleagues (e.g. Goodrich et al.).

For AmpliFast™ sublicensing opportunities please contact .

Return to the Top of the Page

2006 April 11
GWC Technologies presents SPRimager®II array platform at BIO2006 conference in Chicago
Tim Burland, GWC’s President and CEO, today presented the company’s label-free SPRimager®II array platform to attendees at the BIO2006 conference in Chicago. The presentation emphasized the unmatched combination of versatility and affordability of the platform, and detailed its effectiveness for analysis of antibody-antigen interaction, cell receptor profiling, and drug absorption modelling.

Return to the Top of the Page
2006 March 01
Detailed protocol now available for preparing monoclonal antibody arrays direct from ascites fluid for analysis on the SPRimager®II
GWC Technologies today made available detailed experimental procedures for preparation of monoclonal antibody (mAb) arrays by direct spotting of unpurified ascites fluid on SpotReady™ chips. Using mAbs raised against RNA polymerase, exemplar data using mAbs provided by Neoclone Inc. show that measured affinities are indistinguishable for probes made by direct spotting of ascites fluid versus direct spotting of purified antibody.

For access to detailed protocols, please contact your GWC Technologies representative or email .

Return to the Top of the Page

©2010 GWC Technologies
Contact our with any questions or comments.